Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Alere Inc (ALR): This Diagnostics Business Could be A Good Play on Shareholder Activism

Healthways, Inc. (NASDAQ:HWAY) is the most expensively valued among the three. At $17 per share, it is worth around $580 million on the market. The market values Healthways at 14.6 times its trailing EBITDA. Healthways is the provider of specific and personalized interventions to help customers improve physical, emotional and their social well-being, operating in North America, Brazil and Australia. Recently, the company has been upgraded to “buy” by Piper Jaffray analyst Sean Wieland, as he thought Healthways could become the leader in the “population health management” industry. He also raised the company’s target price from $11 to $19 per share. He wrote, “Healthways is the domain expert in population health management, yet has less than a 1% market share in this $1 billion per year opportunity.” In the full year 2013, the company expected to generate $710-$750 million in revenue, with the EPS ranging from $0.25 to $0.35 per share.

My Foolish take

If Alere could sell their non-core businesses and bring more cash back, Alere’s balance sheet would be much stronger. Moreover, the company could focus its resources on its core business to drive the company forward. The expected $50-$100 million in annual savings could also affect its bottom line quite positively in the next several years. Indeed, Alere could be considered a buy at its current price.

Anh HOANG has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson.

The article This Diagnostics Business Could be A Good Play on Shareholder Activism originally appeared on and is written by Anh HOANG.

Anh is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.